Skip to content

The effect of progesterone in the prevention of preterm delivery

Tocolysis vaginal progesterone ether as preservatives in preventing preterm delivery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016112331046N1
Enrollment
200
Registered
2017-05-29
Start date
2015-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm labour without delivery. Preterm labour without delivery

Interventions

Intervention 1: Giving 200mg vaginal progesteronin in case group after confirmed preterm laber and treat with sulfat manuazum and corticosteroid.If the pain isnt offafterr 12 hour it is repeated then
Treatment - Drugs
Giving 200mg vaginal progesteronin in case group after confirmed preterm laber and treat with sulfat manuazum and corticosteroid.If the pain isnt offafterr 12 hour it is repeated then after of control
In control group after confirmed preterm laber none drug inadditon of sulfat manuaziom and corticosteroid is given.

Sponsors

Vice-Chancellor for Research of Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: singleton pregnancies between 24-34 weeks gestational age; premature delivery confirmation by: regular uterine contractions (with a length of more the 30 second and more than 3 times per 10 minutes) with dilatation of the cervix 0-2 centimetres in nolipars and 0-3 centimetre in moltipars; intact fetal membranes. exclusion criteria: rupture of the membranes during treatment; fetal anomaly; any evidence of fetal distress (chorioamnionitis, Preeclampsia, placental abruption, intrauterine growth restriction); sensitivity to progesterone (dizziness, headache, depression, high blood sugar during usage); history of medical illness in the mother (high blood pressure, cancer, epilepsy, chronic thromboambolic disease, liver disease); patients with asthma treated with oral beta-adrenergic.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Delay of delivery. Timepoint: post partum. Method of measurement: documented data.

Secondary

MeasureTime frame
Neonatal distress. Timepoint: after delivery. Method of measurement: Documented data.;Birth weight. Timepoint: After delivery. Method of measurement: Documented data.;Apgar at birth. Timepoint: After delivery in 1 and 5 minutes. Method of measurement: Documented data.;Gestational age at birth. Timepoint: after delivery. Method of measurement: documented data.;Perinatal Mortality. Timepoint: after delivery. Method of measurement: documented data.;Fetal death. Timepoint: after delivery. Method of measurement: documented data.;NICU admission. Timepoint: after delivery. Method of measurement: documented data.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fahimeh Takallo

Kowsar Hospital

fahimeh_takallo@yahoo.com+98 28 3223 6374

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026